100 GENES FOUND
Show / hide columns
XML |
RDF |
TSV |
Page next »
CACNA1A Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit Disease related genes Nucleoplasm Tissue enhanced
CACNA1B Calcium channel, voltage-dependent, N type, alpha 1B subunit Disease related genes Group enriched
CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C subunit Disease related genes Tissue enhanced
CACNA1D Calcium channel, voltage-dependent, L type, alpha 1D subunit Cancer-related genes Nuclear membrane Mixed
CACNA1E Calcium channel, voltage-dependent, R type, alpha 1E subunit Predicted membrane proteins Plasma membrane Tissue enriched
CACNA1G Calcium channel, voltage-dependent, T type, alpha 1G subunit FDA approved drug targets Tissue enhanced
CACNA1H Calcium channel, voltage-dependent, T type, alpha 1H subunit Disease related genes Nucleoplasm Tissue enhanced
CACNA1S Calcium channel, voltage-dependent, L type, alpha 1S subunit Disease related genes Tissue enriched
CATSPER4 Cation channel, sperm associated 4 Predicted membrane proteins Tissue enriched
CNGA1 Cyclic nucleotide gated channel alpha 1 Disease related genes Vesicles Mixed
CNGA2 Cyclic nucleotide gated channel alpha 2 Predicted membrane proteins Not detected
CNGB3 Cyclic nucleotide gated channel beta 3 Disease related genes Tissue enhanced
HCN1 Hyperpolarization activated cyclic nucleotide gated potassium channel 1 Disease related genes Tissue enriched
HCN3 Hyperpolarization activated cyclic nucleotide gated potassium channel 3 Plasma proteins Mixed
KCNA1 Potassium channel, voltage gated shaker related subfamily A, member 1 Disease related genes Tissue enriched
KCNA10 Potassium channel, voltage gated shaker related subfamily A, member 10 FDA approved drug targets Nucleoplasm Tissue enhanced
KCNA2 Potassium channel, voltage gated shaker related subfamily A, member 2 Disease related genes Tissue enriched
KCNA3 Potassium channel, voltage gated shaker related subfamily A, member 3 FDA approved drug targets Mixed
KCNA4 Potassium channel, voltage gated shaker related subfamily A, member 4 FDA approved drug targets Tissue enhanced
KCNA5 Potassium channel, voltage gated shaker related subfamily A, member 5 Disease related genes Tissue enhanced
KCNA6 Potassium voltage-gated channel subfamily A member 6 FDA approved drug targets Not detected
KCNB1 Potassium channel, voltage gated Shab related subfamily B, member 1 Disease related genes Tissue enhanced
KCNB2 Potassium channel, voltage gated Shab related subfamily B, member 2 FDA approved drug targets Nucleoli Tissue enhanced
KCNC1 Potassium channel, voltage gated Shaw related subfamily C, member 1 Disease related genes Nucleus Tissue enriched
KCNC2 Potassium channel, voltage gated Shaw related subfamily C, member 2 FDA approved drug targets Plasma membrane Tissue enriched
KCNC3 Potassium channel, voltage gated Shaw related subfamily C, member 3 Disease related genes Tissue enhanced
KCNC4 Potassium channel, voltage gated Shaw related subfamily C, member 4 Predicted membrane proteins Nucleoli Mixed
KCND1 Potassium channel, voltage gated Shal related subfamily D, member 1 FDA approved drug targets Nucleus Mixed
KCND2 Potassium channel, voltage gated Shal related subfamily D, member 2 Disease related genes Tissue enhanced
KCND3 Potassium channel, voltage gated Shal related subfamily D, member 3 Disease related genes Mixed
KCNF1 Potassium channel, voltage gated modifier subfamily F, member 1 Plasma proteins Golgi apparatus Tissue enriched
KCNG1 Potassium channel, voltage gated modifier subfamily G, member 1 Predicted intracellular proteins Vesicles Tissue enhanced
KCNG2 Potassium channel, voltage gated modifier subfamily G, member 2 Predicted membrane proteins Not detected
KCNG3 Potassium channel, voltage gated modifier subfamily G, member 3 Predicted membrane proteins Cytoplasmic bodies Tissue enhanced
KCNG4 Potassium channel, voltage gated modifier subfamily G, member 4 Predicted membrane proteins Not detected
KCNH1 Potassium channel, voltage gated eag related subfamily H, member 1 Disease related genes Vesicles Tissue enriched
KCNH3 Potassium channel, voltage gated eag related subfamily H, member 3 Predicted membrane proteins Nucleus Group enriched
KCNH5 Potassium channel, voltage gated eag related subfamily H, member 5 Predicted membrane proteins Microtubules Tissue enhanced
KCNH7 Potassium channel, voltage gated eag related subfamily H, member 7 Predicted membrane proteins Tissue enriched
KCNJ1 Potassium channel, inwardly rectifying subfamily J, member 1 Disease related genes Tissue enriched
KCNJ11 Potassium channel, inwardly rectifying subfamily J, member 11 Disease related genes Tissue enhanced
KCNJ12 Potassium channel, inwardly rectifying subfamily J, member 12 FDA approved drug targets Nucleoplasm Group enriched
KCNJ14 Potassium channel, inwardly rectifying subfamily J, member 14 Predicted membrane proteins Nucleoli Mixed
KCNJ15 Potassium channel, inwardly rectifying subfamily J, member 15 Predicted intracellular proteins Vesicles Tissue enhanced
KCNJ16 Potassium channel, inwardly rectifying subfamily J, member 16 Predicted intracellular proteins Vesicles Group enriched
KCNJ2 Potassium channel, inwardly rectifying subfamily J, member 2 Disease related genes Tissue enhanced
KCNJ3 Potassium channel, inwardly rectifying subfamily J, member 3 Plasma proteins Tissue enhanced
KCNJ5 Potassium channel, inwardly rectifying subfamily J, member 5 Cancer-related genes Tissue enhanced
KCNJ8 Potassium channel, inwardly rectifying subfamily J, member 8 Disease related genes Mixed
KCNJ9 Potassium channel, inwardly rectifying subfamily J, member 9 Predicted membrane proteins Tissue enriched
Page next »
